{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:02:16Z","timestamp":1791115336415,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is well known that signals emanating from the B-cell receptor (BCR) activate downstream pathways to regulate the development and survival of normal B cells. In B-cell malignancies, it is increasingly understood that similar pathways are activated through both tonic and chronic active BCR signaling to promote tumor viability and resistance to therapy. Recently, several active and oral agents have emerged that target key proximal kinases in the BCR pathway, including Bruton tyrosine kinase, PI3K, and spleen tyrosine kinase. In early clinical studies, these agents have shown significant activity across a broad range of B-cell lymphomas and chronic lymphocytic leukemia. Especially impressive responses have been reported in mantle cell lymphoma and chronic lymphocytic leukemia, and many patients remain on treatment with continued disease control. Toxicity profiles have been mild in the majority of early studies, without significant myelosuppression over prolonged dosing. Due to these attractive attributes, several agents targeting the BCR pathway are now entering early combination studies with traditional chemotherapeutics and\/or other novel agents. It is clear that agents targeting the BCR pathway will significantly affect the design of future therapeutic regimens for B-cell malignancies. Future research will focus on understanding potential mechanisms of resistance, identifying biomarkers of response, and defining optimal combination regimens.<\/jats:p>","DOI":"10.1182\/asheducation-2013.1.553","type":"journal-article","created":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T15:51:13Z","timestamp":1386345073000},"page":"553-560","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Targeting B-cell receptor signaling: changing the paradigm"],"prefix":"10.1182","volume":"2013","author":[{"given":"Nathan","family":"Fowler","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111704015816600_B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrd3937","article-title":"Targeting pathological B cell receptor signalling in lymphoid malignancies","volume":"12","author":"Young","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"11-12","key":"2019111704015816600_B2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2119\/2008-00102.Catera","article-title":"Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation","volume":"14","author":"Catera","year":"2008","journal-title":"Mol Med"},{"issue":"13","key":"2019111704015816600_B3","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/blood-2008-06-162024","article-title":"Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA","volume":"112","author":"Chu","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111704015816600_B4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J Exp Med"},{"key":"2019111704015816600_B5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Duhren-von Minden","year":"2012","journal-title":"Nature"},{"issue":"1","key":"2019111704015816600_B6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2012-09-454439","article-title":"CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL","volume":"121","author":"Binder","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111704015816600_B7","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.4049\/jimmunol.1300179","article-title":"Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen","volume":"190","author":"Cha","year":"2013","journal-title":"J Immunol"},{"issue":"20","key":"2019111704015816600_B8","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2012-05-427534","article-title":"Self-antigen recognition by follicular lymphoma B-cell receptors","volume":"120","author":"Sachen","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111704015816600_B9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.molimm.2007.10.009","article-title":"Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma","volume":"45","author":"McCann","year":"2008","journal-title":"Mol Immunol"},{"issue":"9","key":"2019111704015816600_B10","doi-asserted-by":"crossref","first-page":"18587","DOI":"10.1073\/pnas.1009388107","article-title":"Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins","volume":"107","author":"Coelho","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111704015816600_B11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2009-06-228015","article-title":"Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins","volume":"115","author":"Craig","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111704015816600_B12","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium","volume":"111","author":"Ekstrom Smedby","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111704015816600_B13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.24287","article-title":"Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies","volume":"125","author":"Anderson","year":"2009","journal-title":"Int J Cancer"},{"issue":"6769","key":"2019111704015816600_B14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"2019111704015816600_B15","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"7089","key":"2019111704015816600_B16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature04687","article-title":"A loss-of-function RNA interference screen for molecular targets in cancer","volume":"441","author":"Ngo","year":"2006","journal-title":"Nature"},{"issue":"7277","key":"2019111704015816600_B17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B cell receptor signaling in diffuse large B cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"5870","key":"2019111704015816600_B18","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"6","key":"2019111704015816600_B19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0092-8674(00)80373-6","article-title":"In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death","volume":"90","author":"Lam","year":"1997","journal-title":"Cell"},{"issue":"3","key":"2019111704015816600_B20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cell.2009.08.041","article-title":"PI3 kinase signals BCR-dependent mature B cell survival","volume":"139","author":"Srinivasan","year":"2009","journal-title":"Cell"},{"issue":"7418","key":"2019111704015816600_B21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"2019111704015816600_B22","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Btk inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111704015816600_B23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111704015816600_B24","first-page":"904","article-title":"Interim results of an international, multicenter, phase 2 study of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up [abstract]","volume":"120","author":"Wang","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111704015816600_B25","first-page":"156","article-title":"The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma [abstract]","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111704015816600_B26","first-page":"189","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib\/II study [abstract]","volume":"120","author":"Byrd","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111704015816600_B27","first-page":"686","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed\/refractory de novo diffuse large b-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study [abstract]","volume":"120","author":"Wilson","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111704015816600_B28","first-page":"8032","article-title":"Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)","volume":"30","author":"Brown","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"16","key":"2019111704015816600_B29","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1158\/1078-0432.CCR-11-1402","article-title":"Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia","volume":"18","author":"Herman","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"31","key":"2019111704015816600_B30","doi-asserted-by":"crossref","first-page":"19236","DOI":"10.1074\/jbc.272.31.19236","article-title":"p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes","volume":"272","author":"Chantry","year":"1997","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111704015816600_B31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"issue":"13","key":"2019111704015816600_B32","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111704015816600_B33","first-page":"1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, An isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma [abstract]","volume":"116","author":"Kahl","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111704015816600_B34","first-page":"55","article-title":"CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]","volume":"116","author":"Furman","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"6","key":"2019111704015816600_B35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.semcancer.2010.09.005","article-title":"Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting","volume":"20","author":"Burger","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"21","key":"2019111704015816600_B36","first-page":"3876","article-title":"A potential therapeutic strategy for chronic lymphocytic leukemia by combining GS-1101, a PI3 kinase delta (PI3K{delta}) inhibitor and a novel highly selective spleen tyrosine kinase (Syk) inhibitor, GS-9973 [abstract]","volume":"120","author":"Burke","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"7","key":"2019111704015816600_B37","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2019111704015816600_B38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111704015816600_B39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"key":"2019111704015816600_B40","first-page":"7070","article-title":"Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-\u03b4,\u03b3, in patients with relapsed\/refractory CLL","volume":"30","author":"Patel","year":"2013","journal-title":"ASCO Meeting Abstracts"},{"issue":"6","key":"2019111704015816600_B41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"2019111704015816600_B42","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111704015816600_B43","first-page":"187","article-title":"The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients [abstract]","volume":"120","author":"Burger","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111704015816600_B44","first-page":"3645","article-title":"Combinations of the phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor Gs-1101 (CAL-101) with rituximab and\/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: results from a phase I study [abstract]","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111704015816600_B45","first-page":"191","article-title":"Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and\/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): results from a phase I study [abstract]","volume":"120","author":"Coutre","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"19","key":"2019111704015816600_B46","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2012-05-431783","article-title":"B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides","volume":"120","author":"Schwamb","year":"2012","journal-title":"Blood"},{"issue":"7332","key":"2019111704015816600_B47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"6","key":"2019111704015816600_B48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"2019111704015816600_B49","first-page":"6515","article-title":"Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)\/rituximab (R) (BR) in patients (pts) with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib\/II study","volume":"30","author":"O'Brien","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"21","key":"2019111704015816600_B50","first-page":"1643","article-title":"A phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin's lymphoma (NHL) [abstract]","volume":"120","author":"Blum","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"2019111704015816600_B51","first-page":"6518","article-title":"A phase I\/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL)","volume":"30","author":"Furman","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"2019111704015816600_B52","first-page":"8502","article-title":"Phase 1b study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL)","volume":"30","author":"Younes","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"key":"2019111704015816600_B53","first-page":"6508","article-title":"A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","volume":"30","author":"Jaglowski","year":"2012","journal-title":"ASCO Meeting Abstracts"},{"issue":"5","key":"2019111704015816600_B54","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111704015816600_B55","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1182\/blood-2008-02-136374","article-title":"Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"111","author":"Malumbres","year":"2008","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/553\/1251149\/bep00113000553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2013\/1\/553\/1251149\/bep00113000553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:02:16Z","timestamp":1573981336000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2013\/1\/553\/20894\/Targeting-Bcell-receptor-signaling-changing-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2013.1.553","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}